Pfizer losses were not as great as expected in the third quarter, but a continued decline in sales of its COVID-19 products clipped revenue. Tuesday’s earnings news follows the Oct. 27 decision to close facilities in Durham and Morrisville
Read More
Pfizer will close facilities in Durham and Morrisville, part of a company wide “realignment” being made, according to a statement, “to operate more efficiently and effectively.” The company, which includes a COVID-19 vaccine in its vast portfolio, reported a drop in sales through the first half of 2023, but...
Read More
Pfizer announced Monday most operations have resumed at its Rocky Mount plant more than two months after a tornado damaged a main building at the site.
Read More
Drug giants GSK and Pfizer, both with a significant presence in North Carolina, are in a legal battle now over respiratory virus vaccines that received FDA approval in May.
Read More
A powerful EF3 tornado touched down near Rocky Mount on July 19, 2023, damaging a storage warehouse at Pfizer’s pharmaceutical manufacturing facility at 4285 N. Wesleyan Blvd. Two weeks after the tornado, on July 31, Pfizer released a report detailing how much product was damaged and if medical professionals and patients will be impacted. Here are the main findings.
Read More
Crumbling COVID-19 vaccine and treatment sales chopped Pfizer’s second-quarter earnings, but both the drugmaker and Wall Street expect a rebound in the back half of 2023. Here’s a look at the latest financials and what could be coming next.
Read More
Tornado damage at the Pfizer plant in Rocky Mount means delays in the availability of some products made there, including drugs used in IV infusions and those injected under the skin or into patient muscles.
Read More
People are picking up the pieces after a violent tornado ripped through Nash and Edgecombe counties Wednesday, leaving a path of destruction in its wake.
Read More
Pfizer topped Wall Street expectations Tuesday even as revenue shrank and sales of its top-selling COVID-19 vaccine crumbled as expected in the first quarter.
Read More
